Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO 2015 - Lung Cancer
Efficacy and Safety of BCD-021, a Bevacizumab Biosimilar Candidate, Compared to Avastin® in Patients with Advanced Nonsquamous NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
,
Biosimilars
Conference Correspondent
Read Article
Final Follow-up Results from RADIANT: Adjuvant Erlotinib Vs Placebo Following Complete Tumor Resection in Patients with Stage IB–IIIA EGFR-positive NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read Article
GASTO 1001: a Phase 2 Trial of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin in Patients with Unresectable Stage III Lung Adenocarcinoma
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read Article
ASCEND-3: a Phase 2 Study of Ceritinib in ALK Inhibitor-Naïve Adult Patients with ALK+ NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read Article
PD-L1, PD-1, and CTLA-4 as Prognostic Biomarkers in Resected NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read Article
First-line Monotherapy with Nivolumab in Advanced NSCLC: Safety, Efficacy, and Correlation of Outcomes with PD-L1 Expression
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Results from the GENIUS Trial: Maintenance Therapy with Gefitinib/Pemetrexed vs Pemetrexed for Metastatic Lung Adenocarcinoma with No Sensitizing EGFR Mutation
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Subgroup Analysis from REVEL: Safety by Histology and Efficacy in Nonsquamous NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Docetaxel plus Ramucirumab vs Docetaxel plus Placebo as Second-line Treatment for Advanced NSCLC: a Phase 2 Multicenter Trial in Japan
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Results from the REVEL Trial: Exposure-Response Relationship for Ramucirumab plus Docetaxel vs Docetaxel as Second-line Treatment of Metastatic NSCLC
ASCO 2015 - Lung Cancer
,
ASCO
Conference Correspondent
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma